Filtered By:
Drug: Herceptin

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition
Conclusions: HER2+ breast cancer cells resistant to trastuzumab continue to be sensitive to PARP inhibition through attenuation of the NF-κB signaling pathway. These results support the use of PARPi as part of a therapeutic strategy for patients with HER2+ breast cancer. Citation Format: Monica E. Wielgos, Tiffiny Cooper, Andres Forero, James A. Bonner, Francisco J. Esteva, C K. Osborne, Rachel Schiff, Albert F. LoBuglio, Eddy S. Yang. Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Wielgos, M. E., Cooper, T., Forero, A., Bonner, J. A., Esteva, F. J., Osborne, C. K., Schiff, R., LoBuglio, A. F., Yang, E. S. Tags: Experimental and Molecular Therapeutics Source Type: research

Therapeutic Targeting of Integrin {alpha}v{beta}6 in Breast Cancer
Conclusions Targeting αvβ6 with 264RAD alone or in combination with trastuzumab may provide a novel therapy for treating high-risk and trastuzumab-resistant breast cancer patients.
Source: JNCI - June 28, 2014 Category: Cancer & Oncology Authors: Moore, K. M., Thomas, G. J., Duffy, S. W., Warwick, J., Gabe, R., Chou, P., Ellis, I. O., Green, A. R., Haider, S., Brouilette, K., Saha, A., Vallath, S., Bowen, R., Chelala, C., Eccles, D., Tapper, W. J., Thompson, A. M., Quinlan, P., Jordan, L., Gillett Tags: Article Source Type: research

ARTN Mediates Acquired Resistance to Trastuzumab Cell Biology
Previous studies have demonstrated that Artemin (ARTN) functions as a cancer stem cell (CSC) and metastatic factor in mammary carcinoma. Herein, we report that ARTN mediates acquired resistance to trastuzumab in HER2-positive mammary carcinoma cells. Ligands that increase HER2 activity increased ARTN expression in HER2-positive mammary carcinoma cells, whereas trastuzumab inhibited ARTN expression. Forced expression of ARTN decreased the sensitivity of HER2-positive mammary carcinoma cells to trastuzumab both in vitro and in vivo. Conversely, siRNA-mediated depletion of ARTN enhanced trastuzumab efficacy. Cells with acquir...
Source: Journal of Biological Chemistry - June 5, 2014 Category: Chemistry Authors: Ding, K., Banerjee, A., Tan, S., Zhao, J., Zhuang, Q., Li, R., Qian, P., Liu, S., Wu, Z.-S., Lobie, P. E., Zhu, T. Tags: Molecular Bases of Disease Source Type: research

High epiregulin expression in human U87 glioma cells relies on IRE1alpha and promotes autocrine growth through EGF receptor
Conclusion: EREG may contribute to glioma progression under the control of IRE1alpha, as exemplified here by the autocrine proliferation loop mediated in U87 cells by the growth factor through ErbB1.
Source: BMC Cancer - December 13, 2013 Category: Cancer & Oncology Authors: Gregor AufArnaud JabouilleMaylis DeluginSylvaine GuéritRaphael PineauSophie NorthNatalia PlatonovaMarlène MaitreAlexandre FavereauxPeter VajkoczyMasaharu SenoAndreas BikfalviDmitri MinchenkoOleksandr MinchenkoMichel Moenner Source Type: research

High epiregulin expression in human U87 glioma cells relies on IRE1¿ and promotes autocrine growth through EGF receptor
Conclusion: EREG may contribute to glioma progression under the control of IRE1alpha, as exemplified here by the autocrine proliferation loop mediated in U87 cells by the growth factor through ErbB1.
Source: BMC Cancer - December 13, 2013 Category: Cancer & Oncology Authors: Gregor AufArnaud JabouilleMaylis DeluginSylvaine GuéritRaphael PineauSophie NorthNatalia PlatonovaMarlène MaitreAlexandre FavereauxPeter VajkoczyMasaharu SenoAndreas BikfalviDmitri MinchenkoOleksandr MinchenkoMichel Moenner Source Type: research

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Abstract: The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti- HER2 monoclonal antibody, approved for the treatment of HER2-positive breast and gastric cancers, exerts only minor complement-mediated cytotoxicity (CDC). Pertuzumab is a novel anti-HER2 monoclonal antibody, which blocks HER2 dimerization with other ligand-activated HER family members. Here, we explored the complement-mediated anti-tumor effects of trastuzum...
Source: Molecular Oncology - February 27, 2013 Category: Cancer & Oncology Authors: Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink Tags: Papers Source Type: research